Publications by authors named "H Mian"
Article Synopsis
- Multiple myeloma (MM) is an incurable cancer affecting older adults, and its prevalence is expected to rise in the next decade due to an aging population.
- Recent advancements in treatment, including immunomodulatory drugs and monoclonal antibodies, have improved outcomes, with ongoing innovations in immunotherapy anticipated for the future.
- This review highlights the importance of assessing patient frailty, outlines treatment goals and options for both newly diagnosed and relapsed MM, and discusses knowledge gaps for improving care in older adults.
Article Synopsis
- - The debate around first line autologous stem cell transplantation (ASCT) for multiple myeloma (MM) has intensified, especially for standard-risk patients, while high-risk patients still face poor treatment outcomes.
- - Current best practices for transplant-eligible MM (TEMM) now include a quadruplet induction therapy that combines an anti-CD38 monoclonal antibody with a proteasome inhibitor and an immunomodulatory drug, followed by maintenance therapy.
- - The Canadian Consensus Guideline Consortium (CGC) is providing recommendations on various aspects of treatment for TEMM, including ASCT eligibility, induction therapy, and management of high-risk patients, with plans to review and update these guidelines regularly.
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature.
Methods: We explored disease characteristics, treatments, and outcomes following modern therapies of young MM patients using the Canadian Myeloma Research Group (CMRG) database. We included 493 patients ≤ 50 years old diagnosed with MM or plasma cell leukemia without concurrent amyloidosis or POEMS syndrome from January 1, 2010, to July 1, 2022.